Risk of venous thromboembolism amongst initiators of SGLT-2 inhibitors compared to other glucose-lowering agents

被引：0
|
作者：
Gopalakrishnan, Chandrasekar [1 ]
Desai, Rishi J. [1 ]
Kim, Seoyoung C. [1 ]
Patorno, Elisabetta [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
3982
引用
收藏
页码：591 / 592
页数：2
相关论文
共 50 条
  • [31] Adoption of New Glucose-Lowering Medications in the US-The Case of SGLT2 Inhibitors: Nationwide Cohort Study
    McCoy, Rozalina G.
    Dykhoff, Hayley J.
    Sangaralingham, Lindsey
    Ross, Joseph S.
    Karaca-Mandic, Pinar
    Montori, Victor M.
    Shah, Nilay D.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (12) : 702 - 712
  • [32] Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care
    Patorno, Elisabetta
    Gopalakrishnan, Chandrasekar
    Brodovicz, Kimberly G.
    Meyers, Andrea
    Bartels, Dorothee B.
    Liu, Jun
    Kulldorff, Martin
    Schneeweiss, Sebastian
    DIABETES OBESITY & METABOLISM, 2019, 21 (08): : 1824 - 1836
  • [33] Acute Kidney Injury Events in Patients With Type 2 Diaoetes Using SGLT2 Inhibitors versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study
    Rampersad, Christie
    Kraut, Eyal
    Whitlock, Reid H.
    Komenda, Paul
    Woo, Vincent
    Rigatto, Claudio
    Tangri, Navdeep
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 76 (04) : 471 - +
  • [34] SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review
    Escobar, Carlos
    Barrios, Vivencio
    Cosin, Juan
    Gamez Martinez, Jose Maria
    Huelmos Rodrigo, Ana Isabel
    Ortiz Cortes, Carolina
    Torres Llergo, Javier
    Requeijo, Carolina
    Sola, Ivan
    Martinez Zapata, M. Jose
    DIABETIC MEDICINE, 2021, 38 (03)
  • [35] Do sodium-glucose link transporter 2 inhibitors (SGLT2i) predispose to venous thromboembolism?
    Brinksman, P.
    Kejem, H.
    Ajay, A.
    Srinivas-Shankar, U.
    DIABETIC MEDICINE, 2022, 39
  • [36] Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review
    Abdi, Hengameh
    Azizi, Fereidoun
    Amouzegar, Atieh
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2018, 16 (02)
  • [37] DAPAGLIFLOZIN ATTENUATES DIABETIC CARDIOMYOPATHY AND THE ACTIVATION OF THE NLRP3/ASC INFLAMMASOME IN MICE WITH TYPE-2 DIABETES: A GLUCOSE-LOWERING AND SGLT-2 INDEPENDENT EFFECT
    Ye, Yumei
    Bajaj, Mandeep
    Birnbaum, Yochai
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 752 - 752
  • [38] COMPARATIVE EFFECTIVENESS OF GLP-1RAS, SGLT-2 INHIBITORS, AND OTHER GLUCOSE-LOWERING DRUGS ON ADVERSE CARDIOVASCULAR AND MORTALITY OUTCOMES AMONG PATIENTS WITH DIABETES, NAFLD, AND CARDIOVASCULAR DISEASES: A LARGE POPULATION-BASED COHORT STUDY
    Krishnan, Arunkumar
    Mukherjee, Diptasree
    Abaalkhail, Faisal
    Woreta, Tinsay A.
    Alqahtani, Saleh A.
    GASTROENTEROLOGY, 2024, 166 (05) : S1660 - S1660
  • [39] DAPAGLIFLOZIN ATTENUATES DIABETIC CARDIOMYOPATHY AND THE ACTIVATION OF THE NLRP3/ASC INFLAMMASOME IN MICE WITH TYPE-2 DIABETES: A GLUCOSE-LOWERING AND SGLT-2 INDEPENDENT EFFECT
    Ye, Y.
    Bajaj, M.
    Hsiu-Chiung, Y.
    Perez-Polo, J. R.
    Birnbaum, Y.
    CARDIOLOGY, 2017, 137 : 198 - 198
  • [40] Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)
    Charalampos I. Liakos
    Dimitrios P. Papadopoulos
    Elias A. Sanidas
    Maria I. Markou
    Erifili E. Hatziagelaki
    Charalampos A. Grassos
    Maria L. Velliou
    John D. Barbetseas
    American Journal of Cardiovascular Drugs, 2021, 21 : 123 - 137
12345